Skip to main content

Table 3 Tumor specimens for which interobserver disagreement arose regarding the results of fluorescence in situ hybridization.

From: HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens

CNB specimens

Code

Final judgment

HER2/CEP17by 1st counts

HER2/CEP17by 2nd counts

  

Obs. A

Obs. B

Average

Obs. A

Obs. B

Average

B61

Amplification

2.71

1.55

2.13

2.55

1.88

2.22

B62

Amplification

2.35

1.88

2.12

2.44

2.07

2.26

B87

Amplification

1.94

2.44

2.19

3.50

2.38

2.44

Surgically resected specimens

Code

Final judgment

HER2/CEP17 by 1st counts

HER2/CEP17 by 2nd counts

  

Obs. A

Obs. B

Average

Obs. A

Obs. B

Average

S67

Amplification

2.67

1.81

2.24

ND

ND

-

  1. HER2 amplification was defined as positive, equivocal, and negative when the HER2/CEP17 ratio was more than 2.2, between 1.8 and 2.2, and less than 1.8, respectively. For the surgically resected specimen, the average of the HER2/CEP17 ratio (2.24) between observers (2.67 and 1.82) was adopted, because the second count was not done (ND). Obs., observer